| P50 | author | José Alexandre de Souza Crippa | Q66605755 |
| P2093 | author name string | Antonio W Zuardi | |
| | Francisco S Guimarães | |
| | Alline C Campos | |
| | Nilson C Ferreira-Junior | |
| | Jaime E Hallak | |
| | Liberato Brum Junior | |
| | Elaine Del-Bel | |
| | Patrícia M da R Zimmermann | |
| P2860 | cites work | Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes | Q72398870 |
| | Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease | Q72649843 |
| | Activational role of cannabinoids on movement | Q73575705 |
| | Cannabidiol Claims and Misconceptions | Q89933715 |
| | Anticonvulsant and Neuroprotective Effects of Cannabidiol During the Juvenile Period | Q91250066 |
| | Effects of Cannabidiol on Diabetes Outcomes and Chronic Cerebral Hypoperfusion Comorbidities in Middle-Aged Rats | Q93085959 |
| | Neuroprotection by cannabidiol and hypothermia in a piglet model of newborn hypoxic-ischemic brain damage | Q93369642 |
| | Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models? | Q22251424 |
| | Meta-analysis of early nonmotor features and risk factors for Parkinson disease | Q22252935 |
| | Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors | Q24642509 |
| | The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin | Q24643876 |
| | The orphan receptor GPR55 is a novel cannabinoid receptor | Q24670137 |
| | Evaluation of Models of Parkinson's Disease | Q26772843 |
| | Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review | Q27005619 |
| | Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 |
| | Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease | Q28244731 |
| | Smoking and Parkinson's disease: systematic review of prospective studies | Q28266994 |
| | Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide | Q28362078 |
| | Parkinson's disease: mechanisms and models | Q29547424 |
| | The molecular logic of endocannabinoid signalling | Q29615356 |
| | Parkinson's disease | Q29616302 |
| | CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum | Q31817073 |
| | Motor actions of cannabinoids in the basal ganglia output nuclei | Q33720160 |
| | From worm to man: three subfamilies of TRP channels | Q33863116 |
| | Substantia nigra and Parkinson's disease: a brief history of their long and intimate relationship. | Q34022505 |
| | Manganese and Parkinson's disease: a critical review and new findings | Q34060040 |
| | The link between the GBA gene and parkinsonism | Q34077492 |
| | Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action | Q34143222 |
| | Metabolic fingerprinting of Cannabis sativa L., cannabinoids and terpenoids for chemotaxonomic and drug standardization purposes | Q34147362 |
| | Chronic exposure to the fungicide maneb may produce symptoms and signs of CNS manganese intoxication. | Q34175721 |
| | Cannabinoid modulation of the dopaminergic circuitry: implications for limbic and striatal output | Q34248777 |
| | Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects | Q34253509 |
| | Hypnotic and antiepileptic effects of cannabidiol. | Q34276401 |
| | Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy | Q34519365 |
| | Protocol for the MPTP mouse model of Parkinson's disease | Q34614573 |
| | Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease | Q34627188 |
| | Cannabidiol for the treatment of psychosis in Parkinson's disease | Q34830827 |
| | Caffeine, postmenopausal estrogen, and risk of Parkinson's disease | Q44357392 |
| | Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. | Q44885114 |
| | Cannabidiol lacks the vanilloid VR1-mediated vasorespiratory effects of capsaicin and anandamide in anaesthetised rats | Q44894284 |
| | Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone | Q44897083 |
| | Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. | Q45303268 |
| | Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. | Q46384445 |
| | Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease | Q46443478 |
| | Paraquat: the red herring of Parkinson's disease research | Q46952974 |
| | Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial | Q48065074 |
| | Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series | Q48105623 |
| | Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. | Q48217036 |
| | Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties | Q48324018 |
| | Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. | Q48631827 |
| | Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action | Q48642582 |
| | Cannabinoids negatively modulate striatal glutamate and dopamine release and behavioural output of acute D-amphetamine | Q48762253 |
| | Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice. | Q48782982 |
| | 6-hydroxy-dopamine induced degeneration of central monoamine neurons | Q49122002 |
| | An acute dose of delta 9-tetrahydrocannabinol affects behavioral and neurochemical indices of mesolimbic dopaminergic activity. | Q51139556 |
| | Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. | Q51985298 |
| | Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. | Q52030475 |
| | The neuroprotection of cannabidiol against MPP⁺-induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson's disease. | Q53281783 |
| | Parkinson's disease | Q54072241 |
| | Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders? | Q55387906 |
| | The pharmacological management of Lennox-Gastaut syndrome and critical literature review | Q58550763 |
| | Antiapoptotic effects of cannabidiol in an experimental model of cognitive decline induced by brain iron overload | Q58769255 |
| | The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson's Disease | Q64785726 |
| | Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys | Q71061579 |
| | 6-Hydroxydopamine Lesion of the Rat Substantia Nigra: Time Course and Morphology of Cell Death | Q71799443 |
| | CB1 cannabinoid receptor signalling in Parkinson's disease | Q35054346 |
| | Description of Parkinson's disease as a clinical syndrome. | Q35170978 |
| | Parkinson disease | Q36319286 |
| | Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism | Q36424540 |
| | Cannabinoid control of motor function at the basal ganglia. | Q36441208 |
| | The 6-hydroxydopamine model of Parkinson's disease | Q36797981 |
| | Epidemiologic studies of environmental exposures in Parkinson's disease | Q36900611 |
| | The cannabinoid system in Parkinson's disease: multiple targets to motor effects | Q37146722 |
| | Paraquat and maneb induced neurotoxicity | Q37208604 |
| | Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action | Q37285921 |
| | The effects of Δ9-tetrahydrocannabinol on the dopamine system. | Q37441554 |
| | Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum | Q37680104 |
| | Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity | Q37683630 |
| | Homeostatic changes of the endocannabinoid system in Parkinson's disease | Q37853933 |
| | What genetics tells us about the causes and mechanisms of Parkinson's disease | Q37947563 |
| | Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? | Q38012845 |
| | Centenary of Lewy bodies (1912-2012). | Q38086092 |
| | Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease | Q38262418 |
| | Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics | Q38275513 |
| | Models of α-synuclein aggregation in Parkinson's disease | Q38286574 |
| | An Introduction to the Endogenous Cannabinoid System | Q38677365 |
| | Animal behavioral assessments in current research of Parkinson's disease. | Q38793201 |
| | Understanding Dopaminergic Cell Death Pathways in Parkinson Disease | Q38838505 |
| | Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor | Q38848638 |
| | Cannabinoid effects on β amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro. | Q39096624 |
| | Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease. | Q39171180 |
| | Endocannabinoid modulation of dopamine neurotransmission | Q39267685 |
| | Regulation of adenylate cyclase by cannabinoid drugs. Insights based on thermodynamic studies | Q42155857 |
| | Hashish. I. The structure of cannabidiol | Q42239859 |
| | Dose and behavioral context dependent inhibition of movement and basal ganglia neural activity by Delta-9-tetrahydrocannabinol during spontaneous and treadmill locomotion tasks in rats | Q42469510 |
| | Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 |
| | Neurobehavioral effects of delta 9-THC and cannabinoid (CB1) receptor gene expression in mice | Q42554293 |
| | Biphasic effects of anandamide | Q43332781 |
| | Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice | Q43694385 |
| | Selective lesion of central dopamine or noradrenaline neuron systems in the neonatal rat: motor behavior and monoamine alterations at adult stage | Q43835685 |
| | Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. | Q43873792 |
| | Postsynaptic endocannabinoid release is critical to long-term depression in the striatum | Q43971441 |
| | Catalepsy induced by intrastriatal injections of Δ9-THC and 11-OH-Δ9-THC in the rat | Q44293969 |
| | Manganese ethylene-bis-dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction | Q44297196 |
| P921 | main subject | Parkinson's disease | Q11085 |
| P577 | publication date | 2019-07-15 | |
| P1433 | published in | Brazilian Journal of Psychiatry | Q7318477 |
| P1476 | title | Biological bases for a possible effect of cannabidiol in Parkinson's disease | |